COMPASS Outperforms TMB and PD-L1 in Survival Stratification
marinkazitnik · x · 2026-07-03
In the retained set of a phase 2 atezolizumab trial for metastatic urothelial carcinoma, the COMPASS model achieved a hazard ratio (HR) separation of 4.7 between responders and non-responders, significantly outperforming traditional TMB and PD-L1 immunohistochemistry scores. The study is a collaboration between Harvard Medical School, the Broad Institute, and the Kempner Institute.
More from Research
- New theory paper explains what Anthropic's Jacobian lens actually detects in LLMs — wgilpin0 · 2026-10-27
- Interpretability researcher joining Goodfire AI post-PhD, calls for speeding up the field — mathildepapillo · 2026-10-27
- EdgeRock-4B holds KV cache at 72 MiB across 256K context, 99.1% smaller than Qwen3.5-4B — alifcoder · 2026-10-27
- TRL adds Score Centering, a simple fix for RLHF training instability — lvwerra · 2026-10-27
- Latent-Foresight: world models that learn to predict their own future — abursuc · 2026-10-27
- UK AISI papers: no good safeguards yet against misuse of biological AI tools — davidmanheim · 2026-10-27